EUCTR2009-016139-36-AT进行中（未招募）不适用
The AT1 receptor antagonist losartan for the prevention of excessive aortic root dilatation in children and adolescents with Marfan syndrom
Medizinische Universität Wien, Univ.Klinik für Kinder-und Jugendheilkunde0 个研究点开始时间: 2009年10月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Marfan diagnosis according to Ghent criteria
- •-Genetic proof of a Fibrillin 1 mutation
- •-age between 1 and 25 years
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Syndroms similar to Marfan Syndrom ( Loeys Dietz syndrom, Shprintzen Goldberg syndrom)
- •- Intolerance approximately ARB
- •- Renal dysfunktion
- •- Aortic root diameter>50mm,waiting for the operation
- •- preceeding Aortic root replacement-therapy
- •- preventive therapy with ß-blokers, calciumcanalblocker,s ace-inhibitors must be terminated
- •- pregnancy
研究者
相似试验
招募中
3 期
Trial of antihypertensive losartan for additional benefit in treating COVID 19 infection.CTRI/2020/05/025319Sanjay gandhi Post Graduate Institute of Medical Sciences
尚未招募
3 期
it is a phase III trial where advanced pancreatic adenocarcinoma patients will be randomised in 2 arms . 1 arm includes losartan given with folfirinox chemotherapy regime and the other arm includes fofirinox chemotherapy only .CTRI/2021/05/033482Tata Memorial Hospital
招募中
不适用
The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney diseasePatient with essential hypertension, diabetic or chronic kidney diseaseJPRN-UMIN000004750Kochi Medical School200
招募中
不适用
The effects of AT1 receptor blocker (telmisartan) on serum lipid with hypertensive patients associated with multiple risk factors for cardiovascular diseaseDiabetes MellitusJPRN-UMIN000007705Chiba University Hospital30
进行中（未招募）
2 期
The use of anakinra in treating complex regional pain syndrome by blocking interleukin-1Refractory complex regional pain syndromeNervous System DiseasesComplex regional pain syndromeISRCTN12908996niversity of Liverpool26